enzalutamide + anastrozole + exemestane + fulvestrant + enzalutamide + exemestane
Phase 1Completed 0 views this week 0 watching💤 Quiet
Interest: 29/100
29
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Breast Cancer
Conditions
Breast Cancer
Trial Timeline
Apr 30, 2012 → Jan 22, 2018
NCT ID
NCT01597193About enzalutamide + anastrozole + exemestane + fulvestrant + enzalutamide + exemestane
enzalutamide + anastrozole + exemestane + fulvestrant + enzalutamide + exemestane is a phase 1 stage product being developed by Astellas Pharma for Breast Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT01597193. Target conditions include Breast Cancer.
What happened to similar drugs?
20 of 20 similar drugs in Breast Cancer were approved
Approved (20) Terminated (4) Active (0)
Hype Score Breakdown
Clinical
6
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01597193 | Phase 1 | Completed |
Competing Products
20 competing products in Breast Cancer